stars 1 stars 2 stars 3

Countagen is a Stockholm-based biotechnology company committed to accelerating the pace of gene editing advancements by providing high-resolution gene editing characterization. Out technology platform, LockSeq, is a novel targeted NGS library preparation based on a unique gap-fill chemistry that minimizes target dropouts and amplification bias, enabling routine and standardized gene editing characterization at every stage of development. The LockSeq Advantage: - Simultaneous Indel Profiling: Profile and validate hundreds of genomic loci in a single reaction. - High Sensitivity: Robust detection of on- and off-target edits down to 0.1% frequency. - Broad Compatibility: Compatibility across sequencing platforms. - Cost-Efficient Scalability: Scale panels and samples with minimal target dropout and uniform target capture. 📍 Based in the SciLifeLab / Karolinska Institutet ecosystem, Solna.

Countagen Questions

Felix Neumann is the CEO and Co-founder of Countagen.

4 people are employed at Countagen.

Top Countagen Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users